Brought to you by 
Series A brings in CHF18mm for Anergis
06 Apr 2011
Executive Summary
Anergis SA (immunotherapies for allergies) has raised CHF18mm ($19.6mm) through its Series A venture round. Vinci Capital & Renaissance PME, BioMedInvest, and Sunstone Capital led the financing (and each contribute one board member) and were joined by Esperante, Initiative Capital Romandie, and several private investors.
Deal Industry
- Pharmaceuticals
-
Pharmaceuticals
- Vaccines
-
Biotechnology
-
Large Molecule
- Antibodies
-
Large Molecule
Deal Status
- Final
Deal Type
-
Financing
- Venture Financing
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Series A brings in CHF18mm for Anergis
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice